Here are five company stocks (Nasdaq prices reflective as of May 31) that some industry analysts say are under the radar and/or could be a great bargain in 2016 per BioSpace.com sources …

1. Agenus: $4.10
Agenus is an immuno-oncology company located in Lexington, Mass., concentrated on the discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer. The company’s broad portfolio of novel checkpoint and other monoclonal antibodies, vaccines and adjuvants work in combination to provide potential best-in-class therapeutic regimens. Prophage, a heat shock protein-based vaccine, has successfully completed Phase II trials in newly diagnosed glioblastoma. Agenus has formed collaborations with Merck and Incyte to discover and develop multiple antibodies.

2. Amarin: $2.08
With headquarters in Dublin, Ireland, Amarin is a biopharma company concentrated on the commercialization and development of therapeutics to improve cardiovascular health. The company’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin’s first FDA approved product is Vascepa (icosapent ethyl), available for use along with a low-fat and low-cholesterol diet to lower high levels of triglycerides (fats) in adults. The company’s most important clinical trial is REDUCE-IT, the first of its kind long-term, prospective cardiovascular outcomes study in high-risk patients on statin therapy.

3. Dimension Therapeutics: $8.00
Based in Cambridge, Mass., Dimension Therapeutics is developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The company’s lead programs address significant medical needs for new therapies and include a wholly owned program in hemophilia B – which entered clinical testing during January 2016 – and others in OTC deficiency, GSDIa, citrullinemia type 1, Wilson disease, and a collaboration with Bayer HealthCare in hemophilia A. Dimension Therapeutics additionally is seeking to expand its pipeline with additional rare disease programs.

4. GlycoMimetics: $8.24
GlycoMimetics is a clinical-stage biotech company using novel and proprietary glycobiology technology to develop treatments for diseases particularly where there is high unmet need. Based on that technology, the Rockville, Md.-based company has developed a robust, diversified product pipeline. GlycoMimetics’ mission is to continue to advance its pipeline, providing hope for patients with sickle cell, cancer, and other serious diseases. The company’ first drug candidate is the pan-selectin antagonist rivipansel. The drug compound is undergoing Phase III development for treating vaso-occlusive crisis in sickle cell disease via a strategic collaboration with Pfizer.

5. Vitae Pharmaceuticals: $10.03
Vitae is a clinical-stage biopharma company located in Fort Washington, Pa. Vitae is focused on discovering and developing novel, small molecule drugs for diseases with significant unmet medical needs. Vitae leverages its structure-based drug design platform, Contour, creating a robust and growing portfolio of product candidates. The company is developing and plans to commercialize multiple product candidates including its innovative RORγt program for treating various autoimmune diseases. In March, Vitae reported positive top-line results from its Phase IIa proof-of-concept clinical trial of VTP-43742 – a wholly owned, first-in-class RORγt inhibitor – in psoriatic patients.